Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2021-03-24 Earnings Release
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Episurf Medical ger covid-19 relaterad uppdatering i samband med investerarkonferens
Earnings Release Classification · 1% confidence The document is a short update from Episurf Medical regarding business activity during the first quarter of 2021, specifically mentioning growth figures and the impact of COVID-19. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR). It provides key highlights and management commentary on recent performance, which aligns best with an Earnings Release (ER). The final paragraph mentions that the information is being made public according to EU market abuse regulation, confirming it is an official announcement of results/updates, not just a presentation or a notice about a report release. Q1 2021
2021-03-24 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Bokslutskommuniké' (Year-end report) for the period 1 October – 31 December 2020. It contains comprehensive financial data, including income statements, balance sheet summaries, management commentary ('Vd har ordet'), and operational highlights for the quarter and the full fiscal year. Since it provides substantive financial results for a period shorter than a full fiscal year (quarterly/year-end interim data) and is not merely an announcement of a report, it is classified as an Interim/Quarterly Report. Q4 2020
2021-02-19 Swedish
Audit Report / Information 2020
Audit Report / Information Classification · 1% confidence The document is titled "Year-end Report 1 October – 31 December 2020" and contains detailed financial metrics for the fourth quarter and the full twelve months of 2020, including net sales, loss for the period, earnings per share, and significant business updates from the CEO. The content is comprehensive, covering operational performance, financial position, and forward-looking statements, which strongly indicates a full periodic financial report. Since it covers the full fiscal year (Year-end Report) and is detailed, it aligns best with the definition of an Annual Report (10-K), although it might be an interim version or a local equivalent. Given the depth of financial review covering the full year, 10-K is the most appropriate classification among the provided options for a comprehensive year-end financial disclosure, rather than just an Earnings Release (ER) or Interim Report (IR). The length (81,139 chars) also suggests a full report, not just an announcement. Q4 2020
2021-02-19 English
Episealer® Patellofemoral System - planned 510(k) submission in Q4 2021
Regulatory Filings Classification · 1% confidence The document announces a planned regulatory submission (510(k) application to the US FDA) for a new medical device system (Episealer® Patellofemoral System) and provides details about the product development, market strategy, and expected timelines (Q4 2021 submission, Q1 2022 feedback). It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific announcement regarding regulatory/product development progress. Since there is no specific category for 'Regulatory Submission Announcement' outside of general regulatory filings, and it details a specific corporate action/update that isn't M&A, financing, or insider dealing, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory announcements not covered by other specific codes. The document length is short (2577 chars), but it is substantive information, not just an announcement of another report's publication.
2021-02-19 English
Episealer® Patellofemoral System - planerad 510(k)-ansökan Q4 2021
Regulatory Filings Classification · 1% confidence The document is a short announcement (2581 characters) from Episurf Medical regarding its plan to submit a 510(k) application to the FDA for a new product system (Episealer® Patellofemoral System) during Q4 2021. It details the product, the regulatory pathway (510(k)), and the expected timeline. This is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it is an announcement about a specific regulatory/product development step and does not fit neatly into the other specific categories like M&A (TAR) or Capital Change (CAP), it falls best under the general 'Regulatory Filings' category (RNS) as a specific regulatory update announcement, or potentially a general announcement about company activity. Given the focus on regulatory submission plans, RNS is the most appropriate fallback for a non-standard, non-financial regulatory update.
2021-02-19 Swedish
Nytt patentbeviljande i USA för Episurf Medical
Regulatory Filings Classification · 1% confidence The document announces a new patent grant in the USA (USPTO) for Episurf Medical concerning a surgical instrument related to their Episealer technology. This is a specific announcement regarding Intellectual Property (IP) protection. Reviewing the definitions, 'IP' (Intellectual Property) is not explicitly listed as a primary code, but the content strongly relates to legal/regulatory protection of assets. The closest fit among the provided codes is 'IP' (Investor Presentation) or potentially 'LTR' (Legal Proceedings Report), but neither fits perfectly as this is a positive IP grant announcement, not a presentation or a lawsuit update. However, since the document explicitly mentions 'IP-skydd' (IP protection) and details a patent, and 'IP' is listed as a code option (Investor Presentation), I must re-evaluate the provided codes against the content. Given the strong focus on a patent grant, and the presence of 'IP' as a code, I will check if 'IP' can be interpreted broadly. Since 'IP' is defined as 'Investor Presentation', and this is clearly not a presentation, I must look for the best fit among the remaining options. The announcement is a specific regulatory/legal update concerning company assets (patents). Since there is no dedicated 'Patent Announcement' code, and it is not a standard financial report (10-K, IR, ER), the most appropriate fallback category for a specific, non-standard regulatory/legal update that doesn't fit elsewhere is 'RNS' (Regulatory Filings/General regulatory announcements). The document ends with a statement about being required to publish under the EU Market Abuse Regulation, confirming its regulatory nature.
2021-02-05 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.